title: Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Baena-Canada
authors.forename: Sara
authors.initials: S
authors.lastname: Estalella
authors.forename: Petra
authors.initials: P
authors.lastname: Rosado
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D044584:Carcinoma, Ductal / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D008207:Lymphatic Metastasis / Q000517:prevention & control; D008209:Lymphedema / Q000139:chemically induced* / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab